Share:
Two articles, published in Contagion Live, provide updates on Paxlovid in relation to the treatment of Long COVID and the treatment of COVID-19 in patients with kidney disease:
Extended Paxlovid treatment shows mixed results for Long COVID
A case series of 13 patients suggests that extended courses of Paxlovid could benefit some Long COVID patients, but the results are inconsistent.
Paxlovid reduces short and long-term adverse outcomes in COVID-19 patients with kidney disease
Recent study highlights Paxlovid’s ability to reduce hospitalizations and mortality in high-risk populations, but underscores the need for personalized treatment.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.